VaxAlta is currently developing several glycoconjugate vaccines that target bacterial pathogens that impact animal health and human food safety (see our list of vaccines in the pipeline below).

VaxAlta also provides contract services to clients applying our proprietary platform technology toward the development of novel glycoconjugate vaccines against any pathogen (bacteria, virus, parasite, etc) where there is a unique glycan to target.

During our glycoconjugate vaccine workflow, VaxAlta also develops testing platforms for quality control that are available to our clients. This includes antibodies specific for the glycan antigen which can be used in diagnostic platforms.


VaxAlta receives the TEC Edmonton Spin-off Award on October 8, 2015.

Sept 24, 2015: Alberta livestock vaccine research gets a $660,000 booster

VaxAlta presenting at GlycoCom 2015 in Banff, Alberta on May 3-5, 2015

Glycoconjugate vaccine pipeline:

Campylobacter species

Campylobacter jejuni (poultry)

Campylobacter fetus venerealis (cattle) and C. fetus fetus (sheep)

Streptococcus species

Streptococcus suis (pigs)

Streptococcus uberis (cattle)

Clostridium perfringens (poultry)

Salmonella species (poultry)

Avian Pathogenic Escherichia coli (poultry)

Get In Touch With Us

Christine Szymanski, Ph.D.
CEO VaxAlta Inc.
AITF iCORE Strategic Chair in Bacterial Glycomics
Professor, Department of Biological Sciences
780-248-1234 (office)
Mario Feldman, Ph.D.
CSO VaxAlta Inc.
CIHR New Investigator - AHFMR Scholar
Associate Professor, Department of Biological Sciences
(780) 492-6105 (office)